AGP Executive Report
Last update: 4 hours agoChikungunya Vaccine: UK regulators revoked Valneva’s authorization for IXCHIQ after reviewing existing safety data; the company said no newly identified safety issue prompted the decision and will not appeal. The withdrawal applies only to the UK: the vaccine remains authorized in the EU, Canada, Brazil and other markets, while its US license was suspended in 2025.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.